You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said that it will soon apply for a CLIA waiver of the second-generation test,which can report positive results in as little as five minutes
The firm said today that it has received all regulatory clearances to close the deal that it first proposed in February 2016.
The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.
Alere this week informed the New York Stock Exchange in writing of its intention to voluntarily delist its Series B convertible perpetual preferred stock from the exchange.
Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.
Under the new purchase terms, Quidel will have direct commercial responsibility for the assays run on Beckman Coulter analyzers. The deal is now valued at $680 million.
Abbott said that greater than 90 percent of the issued and outstanding shares of preferred stock had been tendered as of Sept. 15.
The CDC received clearance for a number of influenza panels and kits. Agilent's assay for postnatal CNV detection, and Abbott's hematocrit test were also cleared.
The firm extended its cash tender offer for all outstanding shares of Alere's Series B convertible perpetual preferred stock until the end of the day on Sept. 15.